The papers I return to.
Here are the papers behind the reading, with a note on what each can answer. A title is only the doorway into an experiment. For a specific claim, I read the participants and outcome next.
Hormone timing and hormone pulses
Ionescu and Frohman’s pulse study follows growth hormone rising and falling during CJC-1295 stimulation. “Pulsatility” means that pattern of release. It doesn’t establish better sleep or long-term health.
Teichman and colleagues’ duration study concerns the DAC form in healthy adults. DAC is an attachment that helps the peptide bind a blood protein. Its half-life estimate describes persistence, not a personal dosing interval.
Gobburu and colleagues’ ipamorelin study used infusions into a vein in healthy men. Its timing findings don’t settle what happens with an injection under the skin.
A treatment trial and a blood marker
Beck and colleagues’ bowel-surgery trial tested whether patients tolerated food sooner. The main comparison didn’t show a clear benefit over placebo. It wasn’t a study of fitness or sleep.
Bolignano and colleagues’ dialysis study followed naturally circulating MOTS-c and later health events. It didn’t test giving the peptide. A marker that tracks health isn’t automatically a treatment.
The registered MOTS-c prediabetes trial describes a planned treatment test in adults with prediabetes and extra weight. The record checked in September 2026 had no results. Registration tells us the question, not its answer.
MOTS-c needs its experimental setting
Lee and colleagues’ first MOTS-c paper studied cells and mice. Its findings helped open the subject, without establishing a treatment benefit in people.
Reynolds and colleagues’ exercise paper gave MOTS-c to mice and measured people’s naturally occurring peptide around exercise. Keeping those experiments separate changes how the title reads.
The human observations aren’t a result from injecting MOTS-c. The mouse performance finding remains an animal finding. I keep returning to that distinction because it changes the conclusion without making the biology any less interesting.
Safety and access have their own sources
The FDA reviews of CJC-1295, ipamorelin and MOTS-c discuss safety concerns and missing evidence. They are evaluations, not approved drug labels.
The FDA bulk-substance safety page distinguishes Category 2 entries from withdrawn nominations. Withdrawal isn’t clearance. The FDA’s compounding explanation describes why compounded medicines aren’t FDA-approved.
The state medical boards’ telemedicine guidance covers licensing and assessment. For another read, the comparison page puts the research questions together while keeping their limits attached.
Keep a question open for the next reading.